Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURE tacrolimus formulation switch study in kidney transplant recipients
NL-OMON59515Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney failure, sponsored by Amsterdam University Medical Center. Primary endpoint: Tacrolimus dose reduction with maintained therapeutic exposure. Started Jan 2021; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney failure
Beyond the preview
Go deeper on NL-OMON59515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59515.